Duyuru • Apr 23
Euroapi S.A., Annual General Meeting, May 27, 2026 Euroapi S.A., Annual General Meeting, May 27, 2026. Location: theatre traversiee, 15 bis rue traversiere, paris France Buy Or Sell Opportunity • Apr 20
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 40% to €1.29. The fair value is estimated to be €1.64, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.5% over the last 3 years. Earnings per share has declined by 42%. Revenue is forecast to decline by 5.0% in 2 years. Earnings are forecast to grow by 82% in the next 2 years. Buy Or Sell Opportunity • Apr 01
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 42% to €1.31. The fair value is estimated to be €1.64, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.5% over the last 3 years. Earnings per share has declined by 42%. Revenue is forecast to decline by 5.0% in 2 years. Earnings are forecast to grow by 82% in the next 2 years. Buy Or Sell Opportunity • Mar 09
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 57% to €1.31. The fair value is estimated to be €1.63, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.5% over the last 3 years. Earnings per share has declined by 42%. Revenue is forecast to decline by 3.9% in 2 years. Earnings are forecast to grow by 85% in the next 2 years. Duyuru • Mar 05
Euroapi S.A. Provides Earnings Guidance for the Fy 2026 Euroapi S.A. provided earnings guidance for the Fiscal Year 2026. For the period, the company expects Net Sales to decrease around 10% on a comparable basis compared to 2025 due to the negative impact of portfolio rationalization (€(55) to (60) million negative impact expected in 202615), reduced demand from Sanofi, and the discontinuation of commercial CDMO contracts. Reported Earnings • Mar 04
Full year 2025 earnings released Full year 2025 results: Revenue: €852.6m (down 7.2% from FY 2024). Net loss: €211.2m (loss widened 62% from FY 2024). Revenue is forecast to grow 3.4% p.a. on average during the next 3 years, compared to a 5.1% growth forecast for the Pharmaceuticals industry in the United Kingdom. Board Change • Jan 06
Less than half of directors are independent Following the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Director Mattias Perjos was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. New Risk • Dec 17
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Buy Or Sell Opportunity • Dec 10
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 6.4% to €3.16. The fair value is estimated to be €2.61, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 2.5% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to decline by 3.5% in 2 years. Earnings are forecast to grow by 80% in the next 2 years. Buy Or Sell Opportunity • Nov 24
Now 23% overvalued after recent price rise Over the last 90 days, the stock has risen 5.6% to €3.22. The fair value is estimated to be €2.61, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 2.5% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to decline by 3.5% in 2 years. Earnings are forecast to grow by 80% in the next 2 years. Buy Or Sell Opportunity • Oct 22
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 2.5% to €3.19. The fair value is estimated to be €2.64, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 2.5% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to decline by 3.5% in 2 years. Earnings are forecast to grow by 80% in the next 2 years. Duyuru • Oct 02
EUROAPI Announces Step Down of Rodolfo J. Savitzky as Independent Director and Chair of the Audit Committee, Effective December 31, 2025 EUROAPI announced that Rodolfo J. Savitzky will step down from his role as EUROAPI’s Independent Director and Chair of the Audit Committee, effective December 31, 2025. The search for a new Independent Director has been initiated, and Rodolfo J. Savitzky’s successor is expected to be appointed before the end of the year. Buy Or Sell Opportunity • Oct 01
Now 23% overvalued after recent price rise Over the last 90 days, the stock has risen 3.7% to €3.22. The fair value is estimated to be €2.61, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 2.5% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to decline by 3.5% in 2 years. Earnings are forecast to grow by 80% in the next 2 years. Reported Earnings • Jul 31
First half 2025 earnings released: €0.30 loss per share (vs €0.37 loss in 1H 2024) First half 2025 results: €0.30 loss per share (improved from €0.37 loss in 1H 2024). Revenue: €414.5m (down 8.1% from 1H 2024). Net loss: €28.5m (loss narrowed 18% from 1H 2024). Revenue is forecast to grow 1.2% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 22 percentage points per year, which is a significant difference in performance. Duyuru • Jul 02
Particle Dynamics, Inc. acquired EUROAPI UK Ltd from Euroapi S.A. (ENXTPA:EAPI). Particle Dynamics, Inc. acquired EUROAPI UK Ltd from Euroapi S.A. (ENXTPA:EAPI) on June 30, 2025. The transaction was completed under financial terms reflecting the fair value of the shares sold. All operations and associated commitments related
to the company will be transferred to Particle Dynamics.
The transaction is expected to have a limited impact on EUROAPI’s H1 2025 consolidated financial statements.
Particle Dynamics, Inc. completed the acquisition of EUROAPI UK Ltd from Euroapi S.A. (ENXTPA:EAPI) on June 30, 2025. New Risk • Jun 26
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€12m net loss in 3 years). Share price has been volatile over the past 3 months (8.2% average weekly change). Duyuru • Apr 17
Euroapi S.A., Annual General Meeting, May 21, 2025 Euroapi S.A., Annual General Meeting, May 21, 2025. Location: theatre traversiere, 15 bis rue traversiere, paris France Reported Earnings • Apr 05
Full year 2024 earnings released: €1.38 loss per share (vs €2.01 loss in FY 2023) Full year 2024 results: €1.38 loss per share (improved from €2.01 loss in FY 2023). Revenue: €919.2m (down 9.8% from FY 2023). Net loss: €130.6m (loss narrowed 31% from FY 2023). Revenue is forecast to stay flat during the next 3 years compared to a 5.0% growth forecast for the Pharmaceuticals industry in the United Kingdom. New Risk • Mar 14
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: €131m Forecast net loss in 3 years: €2.0m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. This is currently the only risk that has been identified for the company. Reported Earnings • Mar 04
Full year 2024 earnings released Full year 2024 results: Revenue: €919.2m (down 9.8% from FY 2023). Net loss: €130.6m (loss narrowed 31% from FY 2023). Revenue is forecast to grow 1.2% p.a. on average during the next 3 years, compared to a 5.2% growth forecast for the Pharmaceuticals industry in the United Kingdom. Duyuru • Mar 04
Euroapi S.A. Provides Earnings Guidance for the Full Year 2025 Euroapi S.A. provided earnings guidance for the full year 2025. For the year, the company expects Net Sales are expected to range from slightly decreasing to steady. This should notably be driven by solid growth in API sales to clients other than Sanofi, particularly in HP APIs, and Opiates, and by double-digit growth in sales from early-phase CDMO, offset by continued reduced API demand from Sanofi, particularly for Sevelamer, a slight decrease in Vitamin B12 sales, and the discontinuation of several pre-carve-out mature CMO projects. New Risk • Jan 02
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (€8.1m net loss in 3 years). New Risk • Dec 02
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€7.0m net loss in 3 years). Share price has been volatile over the past 3 months (7.0% average weekly change). Buy Or Sell Opportunity • Oct 19
Now 20% overvalued after recent price rise Over the last 90 days, the stock has risen 8.8% to €3.32. The fair value is estimated to be €2.76, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last year. Meanwhile, the company became loss making. For the next 3 years, revenue is forecast to decline by 0.2% per annum. Earnings are forecast to grow by 73% per annum over the same time period. Duyuru • Sep 13
Euroapi S.A. to Report Fiscal Year 2024 Results on Mar 03, 2025 Euroapi S.A. announced that they will report fiscal year 2024 results on Mar 03, 2025 Reported Earnings • Aug 02
First half 2024 earnings released: €0.37 loss per share (vs €0.67 profit in 1H 2023) First half 2024 results: €0.37 loss per share (down from €0.67 profit in 1H 2023). Revenue: €450.9m (down 9.5% from 1H 2023). Net loss: €34.8m (down 155% from profit in 1H 2023). Revenue is forecast to stay flat during the next 3 years compared to a 6.0% growth forecast for the Pharmaceuticals industry in the United Kingdom. New Risk • Jul 09
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: €190m Forecast net loss in 3 years: €14m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-€161m). Currently unprofitable and not forecast to become profitable over next 3 years (€14m net loss in 3 years). Share price has been volatile over the past 3 months (7.8% average weekly change). Duyuru • Apr 10
Euroapi S.A. Announces Executive and Executive Committee Changes EUROAPI announced a streamlining of its Executive Committee around operational functions in order to improve focus and efficiency. As part of this move, Guillaume Rosso has been appointed as Chief Commercial Officer, succeeding Laurent Alexandre who has decided to pursue other opportunities outside of the company. The new Executive Committee will be composed of: Antoine Delcour,Chief Financial Officer, Thierry Durand,Chief R&D Officer, Ute Herzog, Chief Human Resources Officer, Cécile Maupas, Chief CDMO Officer, Guillaume Rosso, Chief Commercial Officer, David Seignolle, Chief Operating Officer. Reported Earnings • Mar 01
Full year 2023 earnings released: €2.01 loss per share (vs €0.16 loss in FY 2022) Full year 2023 results: €2.01 loss per share (further deteriorated from €0.16 loss in FY 2022). Revenue: €1.02b (up 3.9% from FY 2022). Net loss: €189.7m (loss widened €174.7m from FY 2022). Revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Pharmaceuticals industry in the United Kingdom. Valuation Update With 7 Day Price Move • Mar 01
Investor sentiment deteriorates as stock falls 41% After last week's 41% share price decline to €3.95, the stock trades at a forward P/E ratio of 9x. Average trailing P/E is 34x in the Pharmaceuticals industry in the United Kingdom. Total loss to shareholders of 74% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €6.51 per share. Buy Or Sell Opportunity • Mar 01
Now 39% undervalued after recent price drop Over the last 90 days, the stock has fallen 24% to €3.95. The fair value is estimated to be €6.51, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.3% over the last year. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 3.9% per annum. Earnings are also forecast to grow by 12% per annum over the same time period. Buy Or Sell Opportunity • Feb 06
Now 23% overvalued after recent price rise Over the last 90 days, the stock has risen 19% to €6.03. The fair value is estimated to be €4.90, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.3% over the last year. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 4.0% per annum. Earnings are also forecast to grow by 11% per annum over the same time period. Duyuru • Nov 29
EUROAPI Announces Executive Changes EUROAPI announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization, focusing on reinforcing robustness and compliance on the entire end-to-end supply chain whilst bringing relevant innovation and product development to support the company's ambition. He will actively oversee the industrial execution of the strategic review announced on October 9, 2023. David Seignolle, a French citizen, joins EUROAPI from Bain & Company where he served as Expert Partner in the Healthcare Practice. Prior to this, David spent 6 years at TEVA where he held several positions such as Head of Operations for Teva API in Italy and Mexico, Vice President Global Supply Chain API and Biologics or Site General Manager. David has also served 5 years at McKinsey & Company in France and in the US where he was focusing on Pharma Operations after beginning his career in Procurement at Toyota Motor Europe. David has a degree in Mechanical Engineering & Industrial Science as well as a postmaster degree in International Procurement Management. Marion Santin, a French citizen, began her career as an associate in law firms, first at Kramer Levin Naftalis & Frankel LLP and then at DLA Piper. She then joined Sanofi in 2006, where she first held the position of Industrial Affairs Legal Manager, then Alliances & Partnerships Legal Director, Mergers & Acquisitions Legal Director before becoming Commercial Operations Legal Director for the legal teams based in Asia, the Middle East, India, Hong Kong and Taiwan. Marion holds an Advanced Degree in Business Law and a Magistère in Business Law from the University of Paris I - Panthéon-Sorbonne. Marion is also a member of the Paris Bar. Duyuru • Nov 22
Euroapi S.A. (ENXTPA:EAPI) completed the acquisition of Bianogmp Gmbh. Euroapi S.A. (ENXTPA:EAPI) signed an agreement to acquire Bianogmp Gmbh for €10 million on August 29, 2023. The total consideration for the transaction is approximately €10 million, including the acquisition price (upfront payment and deferred consideration) and Capex aimed to increase Biano’s capacity to address larger scale and more complex projects. Biano will retain its corporate brand and become a EUROAPI company. The closing of the transaction is subject to customary conditions precedent and is expected in the fourth quarter of 2023.Euroapi S.A. (ENXTPA:EAPI) completed the acquisition of Bianogmp Gmbh on November 21, 2023. As planned, Biano will retain its corporate brand and become a EUROAPI company. New Risk • Oct 11
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (17% average weekly change). Minor Risk Large one-off items impacting financial results. Buying Opportunity • Oct 10
Now 59% undervalued after recent price drop Over the last 90 days, the stock is down 51%. The fair value is estimated to be €12.40, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.3% over the last year. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 5.5% per annum. Earnings is also forecast to grow by 23% per annum over the same time period. Duyuru • Oct 10
Euroapi S.A. Provides Sales Guidance for the Full-Year 2023 Euroapi S.A. provided sales guidance for the full-year 2023. For the year Net Sales are now expected to grow between +3% and +5%, compared to +7% to +8% previously. The slowdown of full-year 2023 Net Sales growth compared to initial expectations is primarily driven by: For API Solutions: the price optimization strategy has recently been impaired by the changing market environment, with pricing pressure resulting from lower overall inflation and destocking programs from some of customers. For the CDMO activities: Net Sales are expected to grow at a slower pace than anticipated due to weaker sales recognition than expected in the fourth quarter. This is notably driven by Biotech companies, with projects delayed, put on hold, or downsized due to funding issues. Duyuru • Aug 31
Euroapi S.A. (ENXTPA:EAPI) signed an agreement to acquire Bianogmp Gmbh for €10 million. Euroapi S.A. (ENXTPA:EAPI) signed an agreement to acquire Bianogmp Gmbh for €10 million on August 29, 2023. The total consideration for the transaction is approximately €10 million, including the acquisition price (upfront payment and deferred consideration) and Capex aimed to increase Biano’s capacity to address larger scale and more complex projects. Biano will retain its corporate brand and become a EUROAPI company. The closing of the transaction is subject to customary conditions precedent and is expected in the fourth quarter of 2023. Reported Earnings • Aug 02
First half 2023 earnings released: EPS: €0.67 (vs €0.18 in 1H 2022) First half 2023 results: EPS: €0.67 (up from €0.18 in 1H 2022). Revenue: €498.5m (up 2.6% from 1H 2022). Net income: €62.8m (up 276% from 1H 2022). Profit margin: 13% (up from 3.4% in 1H 2022). Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Pharmaceuticals industry in the United Kingdom. 
